Stemline Therapeutics (STML) Sees IPO Price of $10 - $12/Share

October 22, 2012 6:00 PM EDT
Stemline Therapeutics (Nasdaq: STML) filed an amended registration with the U.S. SEC for an Initial Public Offering of its Common Stock. The company plans to sell 1,819,000 shares and sees an offering price of $10 to $12 per share. The company plans to list on the Nasdaq under the symbol, "STML."

The offering is being made through Aegis Capital Corp.

Stemline is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Add Your Comment